Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","amount":"$13.1 million","upfrontCash":"$13.1 million","newsHeadline":"Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reunion Neuroscience Doses 1st Patient in Phase 2 Trial of RE104 for Postpartum Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Reunion Neuroscience

    Menu

    Reunion Neuroscience

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Reunion Neuroscience

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Reunion Neuroscience Doses 1st Patient in Phase 2 Trial of RE104 for Postpartum Depression

              Details:

              Reunion Neuroscience's lead product RE104, prodrug of 4-OH-DiPT is being evaluated in the mid-stage clinical trial studies for the treatment of postpartum depression

              Lead Product(s): RE104

              Therapeutic Area: Psychiatry/Psychology Product Name: RE104

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 23, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Reunion Neuroscience

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings

              Details:

              The financing will bolster the company's mid-stage clinical trial studies, particularly focusing on RE104 in postpartum depression, as well as facilitate expansion into additional psychiatric indications.

              Lead Product(s): RE104

              Therapeutic Area: Psychiatry/Psychology Product Name: RE104

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: MPM BioImpact

              Deal Size: $103.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing May 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Reunion Neuroscience

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

              Details:

              MPM BioImpact will develop next-generation solutions for underserved mental health conditions including, RE104, a proprietary, novel, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, being developed for postpartum depression.

              Lead Product(s): Isoprocin Prodrug

              Therapeutic Area: Psychiatry/Psychology Product Name: RE104

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: MPM BioImpact

              Deal Size: $13.1 million Upfront Cash: $13.1 million

              Deal Type: Acquisition June 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY